<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126654</url>
  </required_header>
  <id_info>
    <org_study_id>FJUH110120</org_study_id>
    <nct_id>NCT05126654</nct_id>
  </id_info>
  <brief_title>Partially Hydrolyzed Guar Gum (PHGG) for Amelioration of Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>Development of a Partially Hydrolyzed Guar Gum (PHGG) Based Synbiotic for Amelioration of Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fu Jen Catholic University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fu Jen Catholic University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some components of the diet could promote the growth of certain bacterial strains present in&#xD;
      the intestine, which are closely associated with benefits for host health. An intestinal&#xD;
      commensal Parabacteroides goldsteinii (Pg) was highlighted to be significantly negatively&#xD;
      associated with severity of COPD. Furthermore, the investigators identify the potential&#xD;
      prebiotics (PHGG) which may enrich the abundance of P. goldsteinii and increase the probiotic&#xD;
      effect of P. goldsteinii.&#xD;
&#xD;
      The investigators designed a randomized control study, which enroll adults diagnosed with&#xD;
      COPD. Then the two groups will receive PHGG or not. Stool samples will be collected. The&#xD;
      ameliorative efficacy will be evaluated by questionnaire and lung function test. Intestinal&#xD;
      microbiota and metabolome will be analyzed and the correlation with lung function indices&#xD;
      will be further investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is well known that some components of the diet could promote the growth of certain&#xD;
      bacterial strains present in the intestine, which are closely associated with benefits for&#xD;
      host health. In the previous study, the investigators found that an intestinal commensal&#xD;
      Parabacteroides goldsteinii (Pg) was highlighted to be significantly negatively associated&#xD;
      with severity of COPD. Furthermore, the investigators identify the potential prebiotics&#xD;
      (PHGG) which may enrich the abundance of P. goldsteinii and increase the probiotic effect of&#xD;
      P. goldsteinii. However, the effect of PHGG supplement on compositional and functional&#xD;
      properties of the human microbiota with COPD still remains unclear.&#xD;
&#xD;
      In this proposal, the investigators designed a randomized control study, which enroll adults&#xD;
      diagnosed with COPD. The investigators will review their past medical records and related&#xD;
      image and lung function test. Then the two groups will receive PHGG or not. Stool samples&#xD;
      will be collected. The ameliorative efficacy will be evaluated by questionnaire and lung&#xD;
      function test. Intestinal microbiota and metabolome will be analyzed and the correlation with&#xD;
      lung function indices will be further investigated. In the future, it may be used to&#xD;
      investigate and analyze the change of microbiota and metabolome, then develop possible&#xD;
      treatment options of COPD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Medical Research Council Dyspnea Scale (mMRC)</measure>
    <time_frame>after PHGG 5 gram/day for 1 month</time_frame>
    <description>change of mMRC scale, 0 the best, 4 the worst</description>
  </primary_outcome>
  <primary_outcome>
    <measure>COPD Assessment Test (CAT)</measure>
    <time_frame>after PHGG 5 gram/day for 1 month</time_frame>
    <description>change of CAT (0 the best, 40 the worst)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>St. George's Respiratory Questionnaire (SGRQ)</measure>
    <time_frame>after PHGG 5 gram/day for 1 month</time_frame>
    <description>change of SGRQ score, 0 the best, 100 the worst</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1</measure>
    <time_frame>after PHGG 5 gram/day for 1 month</time_frame>
    <description>change of FEV1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1%</measure>
    <time_frame>after PHGG 5 gram/day for 1 month</time_frame>
    <description>change of FEV1%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FVC</measure>
    <time_frame>after PHGG 5 gram/day for 1 month</time_frame>
    <description>change of FVC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FVC%</measure>
    <time_frame>after PHGG 5 gram/day for 1 month</time_frame>
    <description>change of FVC%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1/FVC%</measure>
    <time_frame>after PHGG 5 gram/day for 1 month</time_frame>
    <description>change of FEV1/FVC%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV3</measure>
    <time_frame>after PHGG 5 gram/day for 1 month</time_frame>
    <description>change of FEV3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV3%</measure>
    <time_frame>after PHGG 5 gram/day for 1 month</time_frame>
    <description>change of FEV3%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV3/FVC%</measure>
    <time_frame>after PHGG 5 gram/day for 1 month</time_frame>
    <description>change of FEV3/FVC%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MMEF</measure>
    <time_frame>after PHGG 5 gram/day for 1 month</time_frame>
    <description>change of MMEF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MMEF%</measure>
    <time_frame>after PHGG 5 gram/day for 1 month</time_frame>
    <description>change of MMEF%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PEF</measure>
    <time_frame>after PHGG 5 gram/day for 1 month</time_frame>
    <description>change of PEF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PEF%</measure>
    <time_frame>after PHGG 5 gram/day for 1 month</time_frame>
    <description>change of PEF%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood cytokine</measure>
    <time_frame>after PHGG 5 gram/day for 1 month</time_frame>
    <description>change of blood cytokine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiota of stool</measure>
    <time_frame>after PHGG 5 gram/day for 1 month</time_frame>
    <description>change of stool microbiota contribution</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>COPD</condition>
  <condition>Microbial Colonization</condition>
  <condition>Respiratory Tract Disease</condition>
  <arm_group>
    <arm_group_label>COPD with PHGG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COPD patient PHGG 5g/day for 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD without PHGG</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>COPD patient without PHGG 5g/day for 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy with PHGG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy PHGG 5g/day for 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy without PHGG</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy without PHGG 5g/day for 1 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Partially Hydrolyzed Guar Gum (PHGG)</intervention_name>
    <description>Partially Hydrolyzed Guar Gum 5 gram/day for 1 month</description>
    <arm_group_label>COPD with PHGG</arm_group_label>
    <arm_group_label>Healthy with PHGG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age of 40-85 years&#xD;
&#xD;
          -  diagnosis of COPD made by pulmonologist&#xD;
&#xD;
          -  provision of written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe and unstable comorbidities or active malignancy&#xD;
&#xD;
          -  COPD exacerbation within the 4 weeks prior&#xD;
&#xD;
          -  cognitive impairment or a psychiatric disorder&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chia-Chen Lu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Respiratory Therapy, College of Medicine, Fu-Jen Catholic University, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yen-Liang Kuo, MD</last_name>
    <phone>886-2-85128888</phone>
    <phone_ext>22030</phone_ext>
    <email>pforcekuo@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yen-Liang Kuo</name>
      <address>
        <city>New Taipei City</city>
        <zip>24205</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yen-Liang Kuo, MD</last_name>
      <email>pforcekuo@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Gut microbiota</keyword>
  <keyword>Respiratory tract</keyword>
  <keyword>prebiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

